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Abstract In the frame of translational breast cancer re-
search, eligibility criteria for formalin-fixed paraffin-
embedded tissue (FFPE) material processing for gene ex-
pression studies include tumor cell content (TCC) and sam-
ple site (primary vs metastatic tumors). Herein we asked
whether the observed differences in gene expression be-
tween paired samples with respect to TCC and sample site
also have different clinical significance. We assessed ESR1,
ERBB2, MAPT, MMP7, and RACGAP1 mRNA expression
with real time PCR in paired samples before (NMD) and
after macrodissection (MD) from 98 primary tumors (PMD,
PNMD) and 72 metastatic lymph nodes (LNMD, LNNMD), as
well as from 93 matched P (mP) and LN (mLN). TCC range
was 2.5–75 % in the NMD series and 28–98 % in the MD
and in the mP/mLN series. The prognostic effect of these
markers, individually or in clusters, remained stable be-
tween paired PMD/NMD. In comparison, cluster classification
failed in the LNNMD group with lower TCC. In the mP/mLN
cohort, RACGAP1 mRNA expression was of prognostic
significance when tested in mLN samples (p<0.001). Sim-
ilarly, luminal B, HER2, and triple negative tumors were of
dismal prognosis when classified in the LN component of
the same series (mLN, overall survival: p00.013, p00.034,
and p00.007, respectively). In conclusion, the clinical rele-
vance of the RNA markers examined may be affected by
TCC in metastatic LN samples but not in primary tumors,
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while it differs between primary tumors and matched me-
tastases. These data will facilitate the design of translational
studies involving FFPE sample series.
Keywords Macrodissection . Tumor cell content . Gene
expression . FFPE . Primary tumor .Metastatic lymph node .
Breast cancer . Translational study
Introduction
Translational studies are increasingly performed on RNA
extracted from formalin-fixed paraffin-embedded (FFPE)
tissue material with quantitative real-time PCR (qPCR) be-
cause it yields analytically accurate results even with de-
graded molecular templates, such as those from FFPE
tissues [1]. Conceivably, sampling is of outmost importance
for obtaining reliable and reproducible results that will be
translated into clinical practice. The initial workflow
involves pathologists who select tissue material from FFPE
tissue banks and evaluate tissue eligibility for RNA extrac-
tion processing. Tumor cell content (TCC) and site of tumor
sample, e.g., for breast cancer usually primary tumors vs
lymph node metastases, are two major parameters that de-
termine tissue sample eligibility for translational studies. In
fact, apart from paraffin block availability, these two param-
eters are major limiting factors for obtaining the large sam-
ple series necessitated for the evaluation of the markers of
interest.
With respect to TCC, a number of studies have shown
that gene expression profiles in normal, cancer, and distinct
elements within each tissue compartment from the same
section may considerably vary [2–7]. However, the impact
of molecular sample TCC on the evaluation of gene expres-
sion markers for their effect on patient outcome has mostly
not been addressed in translational studies, perhaps with the
exception of one [2]. Currently, limiting TCC rates for gene
expression assessments broadly vary in the research setting.
Minimal TCC ranges from 10 [2], 20 [8], 30–50 [9–15], to
70 % [16, 17]. TCC% cutoffs have been validated individ-
ually for diagnostic gene expression applications: 75 % for
the classifier PAM50 (http://www.aruplab.com/guides/ug/
tests/2004700.jsp), 50 % for Oncotype DX (http://www.on-
cotypedx.com/en-US/Breast.aspx), or 30 % for EndoPredict
[18]. For large FFPE samples series but also in the diagnos-
tic setting, the usually applied method for increasing TCC is
macrodissection, i.e., procurement of tissue fragments from
unstained sections with a scalpel [19]. In comparison to the
more precise but costly and time-consuming laser microdis-
section [20], macrodissection is an almost no-cost approach.
However, it is still an extra step in the whole procedure of
extracting DNA/RNA from FFPE sections, meaning extra
time and labor to spend in the course of a large-scale project.
In addition, although several studies have reported vari-
able rates on the concordance of classic breast cancer
parameters (hormone receptor and HER2 status) in primary
tumors and metastatic lymph nodes with slide-based meth-
ods (IHC, mRNA ISH, FISH, CISH) [21–28], knowledge
regarding mRNA expression in the same context is limited.
In translational studies, however, tissue material from meta-
static lymph nodes may occasionally be the only source for
tumor geno/phenotyping.
With the above questions still open, the present study
emerged as a necessity for understanding whether TCC and
assessment in primary tumors vs metastatic lymph nodes
would affect the prognostic significance of gene expression
markers in the frame of translational research. Focused on
these issues, we reevaluated the clinical impact of selected
gene expression markers previously published [10, 13,
29–31] or currently under investigation by our group. Paired
samples were prepared from whole sections (non-macro-
dissected, NMD) and from procured tissue fragments (mac-
rodissected, MD) from routinely processed breast carcinoma
tissues. The mRNA markers assessed were ESR1 (6q25.1,
estrogen receptor-alpha [ER]); ERBB2 (17q21.1, v-erb-b2
erythroblastic leukemia viral oncogene homolog 2,
[HER2]); MAPT (17q21.1, microtubule-associated protein
tau); MMP7 (11q21-q22, metalloproteinase-7); and RAC-
GAP1 (12q13.12, Rac GTPase-activating protein 1). The
role of ESR1 and ERBB2 in breast cancer has been exten-
sively studied and the expression of both genes is used in
molecular breast cancer subtyping [32] and in prognostic
multigene signatures [33, 34]. In breast cancer, MAPT ex-
pression seems to be an independent favorable prognostic
parameter [31] influenced by ER and may be predictive of
response to taxanes [35]. MMP7, one out of many matrix
metalloproteases that are involved in the breakdown of
extracellular matrix in normal physiological processes and
in wound healing, has been shown to promote breast cancer
cell invasiveness in vitro [36]. RACGAP1, a GTPase-
activating protein, is essential for the induction of cytokine-
sis [37] and may therefore promote cancer growth. The
impact of the same mRNA markers on patient outcome




For the purposes of the present study, the clinical records
and tissue material from 369 patients that had participated in
the clinical trial HE10/97 conducted by the Hellenic Coop-
erative Oncology Group were retrieved. Patient and treat-
ment characteristics have previously been published [38];
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briefly, all patients had received dose-dense sequential epi-
rubicin (E) and CMF with or without the addition of pacli-
taxel (T). From this clinical cohort, 349 patient cases, 442
paraffin blocks, and 527 RNA samples were included in the
present study according to (a) availability of gene expres-
sion data for all five mRNA markers examined, (b) matched
non-macrodissected (NMD) and macrodissected (MD)
RNA samples, and (c) matched primary/lymph node RNA
samples. Gene expression was analyzed in three series of
matched RNA samples: (a) MD vs NMD from primary
tumors (P); (b) MD vs NMD from metastatic lymph nodes
[39]; and (c) matched P and LN samples (mP, mLN). The
outline of these study groups is shown in Fig. 1; detailed
patient demographics, clinical data, and standard tumor
characteristics for all paired series are presented in ESM_1
(ESM_1_1). All breast carcinomas were centrally assessed
with immunohistochemistry (IHC) for ER, PgR (scored
according to [40]), and HER2, as well as with FISH for
ERBB2 gene amplification (scored according to [41]). All
patients had signed an informed consent form permitting the
use of their biologic material for research purposes. The
study was approved by the Bioethics Committee of the
Aristotle University of Thessaloniki School of Medicine.
Tissue sections were macrodissected where possible in
cases with <75 % tumor cells in the whole section in order
to increase tumor cell content (TCC) in the molecular sample.
Samples were thus distinguished as MD (macrodissected) and
NMD (non-macrodissected, whole sections) and are referred
to as such throughout this manuscript. Histologic components
were recorded as continuous variables (ESM_1_2). More
details on manual macrodissection are described in ESM_1.
RNA extraction and mRNA expression investigations
RNA extraction from 527 tissue samples was performed
using a fully automated silica-coated magnetic bead-based
method in combination with a liquid handling robot (VER-
SANT Tissue Preparation System, Siemens Healthcare
Diagnostics), as previously described [8, 42]. Details on
RNA extraction and processing with reverse transcription
quantitative real time PCR (RT-qPCR) are described in
ESM_1. The assays used for ESR1, ERBB2, MAPT,
MMP7, and RACGAP1 mRNA expression and their perfor-
mance characteristics are shown in ESM_1_3. Relative
quantification (RQ) values were assessed linearly as (40–
dCT), whereby dCT 0 triplicate mean (CTtarget − CTRPL37A).
Statistics
This study involved paired sample analyses regarding
TCC%, sample site, and RQ values. TCCNMD represents
the percentage of neoplastic cells in the whole section and
TCCMD, the percentage of neoplastic cells in the dissected
tissue area. deltaTCC variables were calculated as TCCMD −
TCCNMD for matched PMD/NMD and LNMD/NMD samples,
and as TCCmLN − TCCmP for the corresponding matched
samples.
RQ values were used as continuous variables throughout
this study. For comparisons of individual mRNA expression
between paired samples, deltaRQ variables were calculated
as follows: deltaRQP ¼ RQ PMDð Þ  RQ PNMDð Þ ; deltaR
QLN ¼ RQ LNMDð Þ  RQ LNNMDð Þ ; and deltaRQP=LN ¼
RQ mLNð Þ  RQ mPð Þ.
TCC percentage, deltaTCC, percentage of normal glan-
dular breast structures, epithelial hyperplasia, and in situ
carcinoma component were correlated with RQ and deltaRQ
values using regression analysis. RQ values were compared
against nominal values (ER/PgR IHC and HER2 status)
using the Mann–Whitney test and for bivariate correlations
with the Spearman’s test. RQ values were also compared for
the same gene in paired samples with the Wilcoxon signed
ranks test. deltaRQ variables were evaluated for changes in
transcript levels between paired sample series with one-






matched P & LN, N = 93 (X2)
matched
MD/NMD LN,
N = 72 (X2)
matched
MD/NMD P,
N = 98 (X2)
b
a
primary tumors (P) with
available RNA data,
N = 307
metastatic lymph nodes (LN)
with available RNA data,
N = 135
93 42214
Fig. 1 Outline of paired sample groups. P, primary tumor; LN, meta-
static lymph node; MD, macrodissected; NMD, non-macrodissected. a
The entire HE10/97 sample series with available RNA expression data
are shown (in total, 442 FFPE tumor blocks from 349 patients).
Matched P and LN samples were available in 93 cases. b Paired sample
groups and overlapping are shown. The matched MD/NMD P series
included 92 and the matched MD/NMD LN series included 72 sample
pairs. Out of the MD/NMD P series, 41 (13+28a) MD samples were
included in the P component of the matched P and LN series. Similarly,
out of the matched MD/NMD LN series, 48 (20+28a) MD samples
were included in the LN component of the matched P and LN series.
Four samples (PMD, PNMD, LNMD, and LNNMD) were available in 28
cases (28a). A subset of P (N0157) and LN samples (N022) shown in
a was not eligible for paired sample analysis, as shown in b
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All above analyses concerned individual markers of gene
expression. However, (a) molecules act in concert in bio-
logical systems, hence their ratios are important; and (b)
changes in RQ values in paired samples might be due to
changes in the expression of the reference gene rather than
of the target gene. Therefore, RQ values of all markers were
profiled for each sample group with hierarchical clustering
by using the JMP v8.0.2 software (SAS). The number of
clusters was selected based on the joint assessment of (a) the
ability of the clusters to form meaningful biological patterns
and (b) the cubic clustering criterion and the pseudo F-
statistic. In order to describe clustered RQ values in matched
paired groups, we used canonical discriminant analysis
measuring the distance between clusters for each sample
group and the contribution of each variable in the clustering
process. Based on these results, clustering concordance was
evaluated with simple Kappa statistics.
The main question addressed in this study was whether
assessing mRNA expression markers in the above-described
different sample series would yield a different prognostic
impact for these markers. For this purpose, individual con-
tinuous ESR1, ERBB2, MAPT, MMP7, and RACGAP1 RQ
variables from each sample group were initially submitted to
univariate Cox analysis for correlations with patient disease-
free (DFS) and overall survival (OS) that were calculated as
previously described [30, 31, 38, 43].
Next, the discriminatory ability of the clusters of the
above RQ values regarding DFS and OS was assessed by
applying the C-index along with the 95 % CI [44, 45].
Clusters were compared against each other in each group
with univariate Cox for assessing the predicted risk of
events with 95 % CI’s.
Results
TCC% in paired sample series and impact on individual
mRNA marker expression
The distribution of TCC% in all sample series examined is
shown in Table 1 and in ESM_2 (ESM_2_1). The higher
efficiency of MD in LN as compared to P samples was
expected based on the more diffuse growth patterns of
primary tumors as compared to metastatic foci in lymph
nodes (examples are shown in ESM_2_2). Matched P and
LN (mP and mLN) series included both MD and NMD
samples. In comparison to the samples of the entire cohort
(Table 1), TCC was >25 % in PMD and LNMD, as well as in
mP and mLN samples.
Variations of relative quantification (RQ) values between
paired samples are shown in Fig. 2 and in ESM_3
(ESM_3_1 and ESM_3_2). deltaRQ values appeared higher
or lower up to more than 6 units corresponding to 6 cycles
because RQ values were calculated linearly. Considering
that 3 cycles correspond to a difference of tenfold in gene
expression, the differences observed in individual matched
pairs reached relative gene expression differences up to
more than a hundredfold, in both directions.
Macrodissection efficiency in increasing TCC% was re-
lated to higher RQ values in LNMD samples for ESR1,
ERBB2, and MAPT, as well as in PMD samples for ERBB2
Table 1 Tumor cell content (TCC%) in the various study cohorts
P LN
























NMD non-macrodissected, MD macro-dissected, P primary, LN meta-
static lymph
aMixed MD and NMD samples
Fig. 2 Difference in the expression of individual ESR1, ERBB2,
MAPT, MMP7, and RACGAP1 mRNA values in paired sample
series. deltaRQ values are shown. P, primary tumor; LN, metastatic
lymph node; MD, macrodissected; NMD, non-macrodissected. For P
and LN MD/NMD pairs, deltaRQ 0 RQMD − RQNMD; for P/LN
pairs, deltaRQ 0 RQmLN − RQmP. Although outliers were found in
both the P and LN series, relative ESR1 and MMP7 mRNA
expression was generally lower in PMD than in PNMD samples (a),
while relative ESR1, ERBB2, and RACGAP1 expression appeared
generally increased in LNMD as compared to LNNMD samples (b).
In matched P/LN samples (c), MMP7 was expressed greater than
tenfold lower in P as compared to matched LN metastases, while
approximately 1/4 of ERBB2 and 1/3 of MAPT RQ values were
more than twofold lower in matched P as well. One-sample t test
95 % CI and significant variability in deltaRQ values are shown

144 Virchows Arch (2013) 462:141–154
mRNA (ESM_3_3). In addition, in primary tumors, the
extent of non-neoplastic breast tissue that was removed
upon MD influenced ERBB2 and RACGAP1, while the
extent of in situ carcinoma areas influenced MMP7 RQ
a b c
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values in PMD samples (ESM_3_4). The associations of
individual marker mRNA expression with classic IHC
parameters (ER, PgR, and HER2) were not altered in PMD
as compared to PNMD samples (ESM_3_5) but varied be-
tween LNMD and LNNMD samples (ESM_3_6) and also
between mP and mLN samples (ESM_3_7). When compar-
ing all results from ESM_3_5, _3_6, and _3_7, it would be
expected that marker associations be preserved in the PMD
and mP, as well as in the LNMD and mLN sample groups.
Such associations were indeed preserved for ESR1 and
ERBB2 expression but not for MAPT, MMP7, and RAC-
GAP1, indicating that the above cohorts were not compara-
ble with each other.
The strongest positive correlations of RQ values were
observed between ESR1 and MAPT in all matched sample
groups (all Spearman’s r>0.5), while positive correlations
between ERBB2 and RACGAP1 were encountered in LN
samples only (all r>0.35) (ESM_3_8). Negative correla-
tions were observed between the RQ values of MMP7 and
ESR1, as well as MAPT, with r values ranging between
−0.23 and −0.35.
Clustering of ESR1, ERBB2, MAPT, MMP7,
and RACGAP1 RQ values
Hierarchical clustering of the five mRNA markers was
applied as described in the “Methods” section in the entire
primary tumor and lymph node samples of the HE10/97
project and revealed four distinct categories of tumors in
each series, with distinct characteristics (Fig. 3). Based on
the above findings, for the biological characterization of
clusters, except for the established roles of ESR1 and
ERBB2 in breast cancer, we considered MAPT as a marker
reflecting estrogen receptor activity [35] and RACGAP1 as a
marker of proliferating cells [46]. Clusters were designated
according to the established molecular subtypes of breast
cancer as luminal A (LumA), luminal B (LumB), HER2-
enriched (HER2), and triple negative (TN) (Fig. 3). These
clusters were obtained for PMD and PNMD samples, for
LNMD, and for mP and mLN samples. In the LNNMD series,
the LumB cluster could not be formed, since it was repre-
sented by only one sample. Cluster discrimination in the
paired sample series is shown in Fig. 4. Clusters LumA and
LumB showed considerable overlapping in all groups, while
HER2 and TN clusters were sharply distinguished. MMP7
RQ values had the lowest determinant role in cluster forma-
tion, while the role of RACGAP1 varied in the different
sample groups. Detailed cluster statistics showing analogies
between standardized values, driver genes, and discrimina-
tion ability are shown in ESM_4 (ESM_4_1 to ESM_4_4).
Cluster concordance in paired sample groups is shown in
ESM_4_5. Importantly, although cluster concordance for
paired groups ranged from only from 64 to 80 %, it did
not statistically differ in samples with TCC <20 % vs those
with original TCC ≥20 % within the same paired sample
series (ESM_4_6). Finally, cluster associations with stan-
dard breast cancer markers, such as ER IHC and HER2
status determined in primary tumors only, were statistically
significant for all comparisons (ESM_4_7).
Comparison of ESR1, ERBB2, MAPT, MMP7,
and RACGAP1 mRNA expression, individually
and clustered, with patient outcome
As shown in Table 2, no strongly significant differences
were observed with respect to TCC% for ESR1, ERBB2,
MAPT, MMP7, and RACGAP1 mRNA, when these markers
were analyzed individually as continuous variables in paired
PMD/NMD and LNMD/NMD samples. The only weak differ-
ence concerned the unfavorable prognostic effect of rela-
tively highMMP7 in PMD, which was not observed in paired
PNMD samples. This may be explained because MMP7 is a
stromal marker, and PMD samples are expected to contain
more tumor–stroma-specific mRNA than PNMD samples.
However, hazard ratios and 95 % confidence intervals for
MMP7 were similar in PMD and in PNMD. Thus, the ob-
served difference in MMP7 statistical significance between
PMD and PNMD samples was not considered as clinically
significant. Similarly, the difference observed for relatively
high MAPT as a favorable prognosticator for patient OS in
mLN, but not in mP samples, was also not considered as
clinically relevant. In this mP/mLN paired series, relatively
high RACGAP1 was strongly associated with unfavorable
DFS and OS only when examined in mLN samples
(Table 2). However, these differences appeared to be
paired sample cohort-specific, since, when examined in
the entire HE10/97 population, RACGAP1 was an unfa-
vorable prognostic parameter when examined in both
primary tumor and in metastatic lymph node series.
For cluster analysis with respect to patient outcome,
cluster discrimination based on the C-index did not reveal
any differences for both DFS and OS between paired
groups, as shown in ESM_5 (ESM_5_1). Accordingly, no
difference was observed in the prognostic relevance of the
four clusters in PMD as compared to the PNMD group (Table 3
and Fig. 5a). The paired LNMD/NMD groups were practically
Fig. 3 Biological relevance of the four-cluster model. Hierarchical
clustering was set to define four clusters corresponding to LumA
(ESR1 and MAPT high), LumB (ESR1 high and high RACGAP1/
MAPT), HER2 (HER2 high/ESR1 and MAPT low), and TN (ESR1,
HER2 and MAPT low) breast cancer subtypes, as shown in a and b.
These clusters were initially identified in the entire series of primary
tumor (P) and metastatic lymph node (LN) of the HE10/97 cohort. c
The major analogies observed in b were preserved in paired sample
series for LumA, LumB, HER2, and TN. LumB could not be identified
in LNNMD samples. Standardized values correspond to mean of 0 and a
standard deviation of 1
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not comparable for cluster performance, since LumB could
not be formed in the LNNMD samples. Instead, LumA and
especially TN tumors were overrepresented in this group,
yielding statistically significant results (Table 3 and Fig. 5b).
In comparison, the more accurately classified HER2 clusters
were associated with worst prognosis in both LNMD and
LNNMD series. Cluster comparisons for patient outcome in
the mP/mLN series revealed the expected worse perfor-
mance of LumB, HER2, and TN in comparison to LumA
tumors only in the mLN series (Table 3 and Fig. 5c). Finally,
in the entire HE10/97 P and LN cohorts, the same prognos-
tic significance was revealed for the four clusters in P
samples unrelated to TCC%, while comparable significance
was observed in LN samples with higher TCC% only
(ESM_5_2).
Multivariate COX analysis was applied in each one of the
paired groups and in the entire HE10/97 sample cohorts for
observing the interference of the obtained clusters with
standard clinicopathologic parameters (age, menopausal sta-
tus, grade, tumor size, number of metastatic lymph nodes,
chemotherapy regimen, hormonal therapy, ER and PgR
IHC, and HER2 status) in paired sample series. The statis-
tically significant results from this analysis are presented in
ESM_5_3. The clinical significance of these findings should
be assessed with caution, because small sample numbers for
several categories and possible cohort specificity of the
clusters yielded large confidence intervals, implying that
the observed hazard ratios may not replicate in a future
study. Besides cohort specificity of the findings, it should
be noticed that calling a tumor as HER2-positive by IHC/
FISH and as HER2-enriched by RQ-value clustering was
not necessarily identical (ESM_4_7). Overall, though, haz-
ard ratios for the clusters in the univariate (Table 3) and in
the adjusted multivariate analysis (ESM_5_3) were either
close to each other, or they were at least in the same
direction (favorable or unfavorable).
Discussion
The purpose of this study was to investigate whether TCC in
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Fig. 4 LumA, LumB, HER2, and TN clusters in paired primary and
lymph node samples. Canonical discriminant structure is shown for
macrodissected/non-macrodissected (MD/NMD) primary tumors (a),
metastatic lymph nodes (LN) MD/NMD (b), and matched primary
tumors and metastatic lymph nodes (mP/mLN) (c). Blue, LumA; red,
LumB; green, HER2; brown, TN. Clusters in A and C followed the
same pattern of discrimination and overlapping, which differed in the
LN MD/NMD series
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Table 2 Impact of TCC% and tumor site on the clinical relevance of gene expression markers in paired sample groups (univariate Cox analysis
with RNA markers as continuous variables)
Sample group Marker Disease-free survival Overall survival
HR CI 95 % Wald's p HR CI 95 % Wald's p
Primary tumors, matched MD/NMD pairs, N098
MD ESR1 0.98 0.86–1.11 0.7034 0.98 0.85–1.14 0.8225
ERBB2 1.07 0.90–1.26 0.4577 1.04 0.84–1.27 0.7301
MAPT 0.87 0.75–1.01 0.0604 0.88 0.74–1.05 0.1605
MMP7a 1.26 1.03–1.53 0.0226 1.26 1.01–1.59 0.0432
RACGAP1 1.37 1.01–1.86 0.0415 1.86 1.29–2.67 0.0008
NMD ESR1 1.01 0.88–1.15 0.9194 1.02 0.87–1.19 0.8425
ERBB2 1.07 0.88–1.29 0.5067 1.03 0.82–1.30 0.7967
MAPT 0.89 0.75–1.06 0.1803 0.92 0.75–1.13 0.4419
MMP7 1.10 0.90–1.33 0.3592 1.13 0.90–1.41 0.2957
RACGAP1 1.31 0.99–1.73 0.0569 1.66 1.22–2.27 0.0013
Metastatic lymph nodes, matched MD/NMD pairs, N072
MD ESR1 0.91 0.81–1.03 0.1314 0.88 0.76–1.03 0.1076
ERBB2 1.23 1.06–1.44 0.0079 1.18 0.96–1.44 0.1212
MAPT 0.84 0.71–1.00 0.0530 0.77 0.62–0.96 0.0183
MMP7 1.16 0.99–1.35 0.0615 1.21 0.99–1.46 0.0564
RACGAP1 2.12 1.40–3.22 0.0004 2.77 1.51–5.08 0.0010
NMD ESR1 0.89 0.76–1.04 0.1537 0.87 0.72–1.05 0.1442
ERBB2 1.27 1.08–1.48 0.0035 1.11 0.91–1.37 0.3051
MAPT 0.89 0.71–1.11 0.3098 0.71 0.53–0.96 0.0283
MMP7 1.15 0.97–1.38 0.1151 1.07 0.86–1.32 0.5397
RACGAP1 1.76 1.34–2.30 0.0001 1.40 1.05–1.86 0.0223
Primary tumors and matched metastatic lymph nodes, N093
Primary tumours ESR1 0.98 0.87–1.10 0.6956 0.93 0.80–1.07 0.2891
ERBB2 0.98 0.83–1.16 0.8369 0.92 0.74–1.14 0.4393
MAPT 0.94 0.83–1.07 0.3526 0.93 0.80–1.09 0.3881
MMP7 1.01 0.84–1.23 0.8890 1.05 0.83–1.31 0.7039
RACGAP1 1.19 0.88–1.61 0.2652 1.45 0.99–2.11 0.0541
Metastatic lymph nodes ESR1 0.95 0.85–1.06 0.3337 0.93 0.82–1.06 0.2648
ERBB2 1.07 0.93–1.23 0.3399 1.05 0.88–1.25 0.5719
MAPTa 0.91 0.80–1.03 0.1344 0.84 0.72–0.98 0.0275
MMP7 1.05 0.92–1.19 0.4793 1.06 0.90–1.24 0.5030
RACGAP1b 1.82 1.29–2.57 0.0006 2.27 1.43–3.58 0.0005
Entire HE 10/97 cohort
Primary tumors, N0315 ESR1 0.94 0.88–1.00 0.0656 0.90 0.84–0.97 0.0071
ERBB2 1.10 1.01–1.20 0.0256 1.09 0.98–1.20 0.1098
MAPT 0.91 0.85–0.98 0.0081 0.89 0.82–0.97 0.0095
MMP7 1.06 0.97–1.16 0.1980 1.06 0.95–1.18 0.2870
RACGAP1 1.30 1.09–1.54 0.0026 1.48 1.20–1.82 0.0002
Metastatic lymph nodes, N0135 ESR1 0.93 0.85–1.02 0.1416 0.91 0.82–1.01 0.0841
ERBB2 1.07 0.95–1.20 0.2629 1.08 0.94–1.24 0.2749
MAPT 0.90 0.80–1.00 0.0509 0.85 0.75–0.97 0.0183
MMP7 1.05 0.94–1.17 0.3772 1.05 0.91–1.20 0.5234
RACGAP1 1.63 1.22–2.17 0.0010 1.86 1.30–2.67 0.0008
MD macrodissected (higher TCC%), NMD non-macrodissected (lower TCC%), CI confidence intervals, HR hazard ratios
aWeak differences between paired sample groups, as indicated by the respective CI 95 % and HR
b Significant difference for RACGAP1 expression as an unfavorable marker in metastatic lymph nodes but not in the paired primary tumors
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applied RNA markers in breast cancer research. Our data
show that, independently of molecular sample TCC rate,
RNA clusters with the markers examined yield the same
prognostic information. This appears as a paradox but it is
not, since clusters are, basically, ratios between marker
measurements. Thus, although individual marker measure-
ments do vary between matched samples with low and high
TCC, as previously established [2–7], their analogies in
such samples from the same tumor seem to be preserved.
These results are in concordance with the only relevant
published study so far [2], which employed fresh tissues
from a limited number of patients, multiple sites from the
same section, and microarray gene profiling. Our findings
are also in line with a more recent study [47] showing that
normal tissues in the presence of breast cancer may express
the same ER-positive or ER-negative gene profiles as the
hosted tumor, in a broad sense of field cancerization.
It is impossible and inapplicable to suggest a safe TCC
cutoff for assessing RNA markers in primary tumor samples
based on the results of the present study. For establishing an
Table 3 Univariate COX com-
parison of cluster prognostic
value in paired sample groups
(Wald’s p)
Bold values indicate significant
differences observed between
comparable paired sample
groups; italicized values indicate
significant difference between
LN MD/NMD paired samples
due to overrepresentation of the
TN cluster in the LNNMD group,
where the luminal B cluster
could not be formed
HR hazard ratio, CI confidence
interval, P primary tumor, LN
metastatic lymph node, MD
macrodissected, NMD non-
macrodissec ted , TN t r ip le
negative
aBroad 95 % CI’s were observed
in these cases because of the lim-
ited number of events in the lu-
minal A patient population
Sample group Comparison Disease-free survival Overall survival
HR 95 % CI p HR 95 % CI p
P, MD Lum B vs Lum A 4.63 1.96–10.95 0.0005 6.02 2.11–17.12 0.0008
HER2 vs Lum A 2.81 0.92–8.58 0.0705 2.43 0.58–10.20 0.2248
TN vs Lum A 4.28 1.40–13.12 0.0110 5.11 1.37–19.06 0.0152
Lum B vs HER2 1.65 0.60–4.55 0.3318 2.48 0.70–8.80 0.1612
Lum B vs TN 1.08 0.39–2.98 0.8779 1.18 0.38–3.66 0.7770
HER2 vs TN 0.66 0.19–227 0.5050 0.48 0.11–2.13 0.3317
P, NMD Lum B vs Lum A 3.34 1.25–8.97 0.0165 13.26 1.76–100.1a 0.0122
HER2 vs Lum A 2.68 0.82–8.78 0.1043 8.12 0.91–73.34a 0.0601
TN vs Lum A 4.20 1.00–17.67 0.0502 20.20 2.09–195.1a 0.0094
Lum B vs HER2 1.25 0.50–3.13 0.6348 1.62 0.54–4.85 0.3887
Lum B vs TN 0.80 0.23–2.70 0.7147 0.66 0.19–2.26 0.5051
HER2 vs TN 0.64 0.16–2.56 0.5253 0.41 0.09–1.82 0.2382
LN, MD Lum B vs Lum A 2.15 0.74–6.22 0.1583 2.71 0.68–10.83 0.1596
HER2 vs Lum A 3.1 1.28–7.9 0.0176 3.71 1.08–12.72 0.037
TN vs Lum A 0.42 0.05–3.4 0.4184 0.95 0.11–8.63 0.9669
Lum B vs HER2 0.69 0.25–1.92 0.4802 0.73 0.21–2.5 0.6154
Lum B vs TN 5.08 0.61–42.2 0.1325 2.83 0.31–25.58 0.3533
HER2 vs TN 7.33 0.93–57.5 0.0581 3.89 0.48–31.74 0.2051
LN, NMD Lum B vs Lum A
HER2 vs Lum A 4.86 1.79–13.16 0.0019 6.21 1.54–24.97 0.0101
TN vs Lum A 2.42 0.88–6.69 0.088 4.6 1.19–17.82 0.027
Lum B vs HER2
Lum B vs TN
HER2 vs TN 2.01 0.77–5.22 0.154 1.35 0.45–4.03 0.5922
Matched P Lum B vs Lum A 2.15 0.86–5.35 0.101 3.01 0.86–10.54 0.0841
HER2 vs Lum A 2.17 0.75–6.28 0.1512 2.55 0.61–10.69 0.202
TN vs Lum A 1.3 0.26–6.49 0.7431 3.23 0.53–19.53 0.2025
Lum B vs HER2 0.99 0.43–2.24 0.9758 1.18 0.42–3.33 0.7492
Lum B vs TN 1.64 0.38–7.04 0.5041 0.93 0.21–4.13 0.9287
HER2 vs TN 1.66 0.35–7.84 0.5204 0.79 0.15–4.13 0.7793
Matched LN Lum B vs Lum A 3.47 1.29–9.32 0.0137 13.32 1.71–103.5a 0.0133
HER2 vs Lum A 3.83 1.25–11.78 0.019 10.21 1.19–87.75a 0.0343
TN vs Lum A 3.24 0.86–12.12 0.0811 20.6 2.24–189.4a 0.0075
Lum B vs HER2 0.9 0.40–2.07 0.8125 1.31 0.44–3.88 0.6315
Lum B vs TN 1.07 0.36–3.15 0.901 0.65 0.21–1.98 0.445
HER2 vs TN 1.18 0.36–3.94 0.7835 0.5 0.13–1.96 0.3167
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optimal cutoff, multiple RNA samples should have been
prepared from every single histological sample with various
but precise TCC rates (for example, 10, 30, 50, 70, and
100 %), involving the same tumor site (for example, tumor
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Fig. 5 Comparison of overall patient outcome according to LumA,
LumB, HER2 and TN classification of primary tumors and their
metastases in lymph nodes. a Clusters are compared in paired groups
from primary tumors (P), macrodissected (MD), and non-
macrodissected (NMD). b Clusters are compared in paired metastatic
lymph node (LN) MD and NMD samples. c Matched P and LN
samples. Log-rank test significance is shown. Blue, LumA; red, LumB;
green, HER2; brown, TN
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front). Further, in order to obtain adequate statistical power,
the major breast cancer subtypes and the multiplicity of non-
cancerous histological elements and tumor microenviron-
ment, which would be contained in the 100–TCC% of the
sample, should be considered in large numbers. To our
knowledge, a study taking into account all of the above
parameters has not yet been performed. Our data show that
the 10 % TCC previously described [2] may not be irrele-
vant for assessing RNA markers in primary breast tumor
samples. A safe conclusion from the present study may be
that the commonly published 70 or 75 % TCC cutoff as an
eligibility criterion for primary tumors seems overrated and
results in the exclusion of large numbers of samples from
translational study cohorts, thereby lowering the statistical
power of such studies. Clearly, the low TCC allowance for
RNA investigations should not apply for DNA studies [48].
In comparison to primary tumors, TCC seemed to affect
the clinical relevance of clusters in metastatic lymph nodes,
although not of single markers. This condition may be
RACGAP1-related, since this marker is expressed in lym-
phocytes as well [46] and will not be tumor-specific in a
lymph node environment. However, the clinical relevance of
these clusters in the LNMD and in the mLN groups was not
the same, suggesting sample cohort bias, which is expected
in fragmented sample series. Hence, TCC alone did not
seem to determine the clinical relevance of the markers
examined in the present study in metastatic lymph node
samples.
Our data also suggest that it is ineligible to substitute for
primary tumor samples with lymph node metastases and
vice versa for translational study purposes, since the same
RNA markers may have different clinical relevance when
examined in each setting. Regional lymph node metastases
are usually diagnosed simultaneously with the primary tu-
mor and are, hence, not considered as a metachronous
disease development. These regional metastases may not
share the phenotypic characteristics of the primary tumor
[22, 24–27, 49], one of the reasons being the evolution of
different metastatic clones from a heterogeneous genetic
background in the primary tumor [50]. Although, again,
cohort bias may underlie the presented results from the mP
and mLN series, our data indicate that when histologic
material from both primary tumor and metastatic lymph
nodes is available, it may be more informative, for example,
to evaluate the HER2-enriched subtype in lymph nodes than
in primary tumors. Whether such an approach should be
integrated into practice for clinical decision-making is a
question to be answered in prospective studies.
Concerning individual markers, RACGAP1 has recently
been revealed as a proliferation marker associated with
prognosis in breast cancer [51, 52]. Herein we show that
its expression may undergo changes similar to those de-
scribed for Ki-67 in metastatic lymph nodes vs primary
tumors [24], which, at least in the present series, seemed
ERBB2-related. In addition, MMP7 expression, a marker of
epithelial–mesenchymal transition in colorectal cancer [53]
and of invasiveness of breast cancer cells in vitro [36], may
be associated with adverse outcome in a subset of primary
breast carcinomas that needs to be defined.
Overall, in line with the previously described intrinsic
characteristics of breast cancer [32, 54–56], the major genes
determining the molecular subtypes in the four clusters were
ESR1 and ERBB2, followed by the ER-dependent MAPT
and by the proliferation marker RACGAP1. The stromal
factor MMP7 did not significantly contribute in this rough
subtype classification. The present study shows that, when
examining RNA markers which are involved in pathways
that are drivers in cancer cells but are of low activity in the
coexisting non-cancer cells, such as in primary tumors sur-
rounded by non-neoplastic breast tissue elements, TCC%
may be of low importance for obtaining clinically relevant
results. By contrast, when the same markers are examined in
an environment where some of them may be expressed in
non-cancerous cells, such as the proliferation pathway in
lymph nodes bearing breast cancer metastases, TCC% may
influence the prognostic significance of these markers. With
the reservation that the results concerning “quantitative” or
semiquantitative RNA markers, individually or in profiles,
are overall cohort-specific in retrospective studies, our data
may contribute to a more efficient and rational design of
translational studies on FFPE tissues.
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